Clinical Trial Update: Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A phase 3 trial evaluating maintenance IRESSA (gefitinib) after front-line platinum-based chemotherapy in advanced or metastatic non-small cell lung cancer has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Non-Small-Cell Lung Carcinoma | Phase 3 | Status: WITHDRAWN